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Pneumocystis jirovecii is a major opportunistic pathogen that causes Pneumocystis pneumonia (PCP) and re-
sults in a high degree of mortality in immunocompromised individuals. The drug of choice for PCP is typically
sulfamethoxazole (SMX) or dapsone in conjunction with trimethoprim. Drug treatment failure and sulfa drug
resistance have been implicated epidemiologically with point mutations in dihydropteroate synthase (DHPS)
of P. jirovecii. P. jirovecii cannot be cultured in vitro; however, heterologous complementation of the P. jirovecii
trifunctional folic acid synthesis (PjFAS) genes with an E. coli DHPS-disrupted strain was recently achieved.
This enabled the evaluation of SMX resistance conferred by DHPS mutations. In this study, we sought to de-
termine whether DHPS mutations conferred sulfa drug cross-resistance to 15 commonly available sulfa drugs.
It was established that the presence of amino acid substitutions (T517A or P519S) in the DHPS domain of PjFAS
led to cross-resistance against most sulfa drugs evaluated. The presence of both mutations led to increased
sulfa drug resistance, suggesting cooperativity and the incremental evolution of sulfa drug resistance. Two
sulfa drugs (sulfachloropyridazine [SCP] and sulfamethoxypyridazine [SMP]) that had a higher inhibitory
potential than SMX were identified. In addition, SCP, SMP, and sulfadiazine (SDZ) were found to be capable
of inhibiting the clinically observed drug-resistant mutants. We propose that SCP, SMP, and SDZ should be
considered for clinical evaluation against PCP or for future development of novel sulfa drug compounds.
Pneumocystis jirovecii is a major opportunistic pathogen that
results in Pneumocystis pneumonia (PCP) of AIDS patients
and immunocompromised individuals. It accounts for 40% of
all AIDS-defining conditions and is the major cause of mor-
tality of children with AIDS in Africa (2, 16).
Clinically, PCP has been treated with antifolates including
combination therapy with sulfamethoxazole (SMX) and tri-
methoprim (TM) as the preferred first-line treatment (19).
Sulfa drugs are inhibitors of folic acid synthesis (FAS). In
fungi, including Candida albicans, Saccharomyces cerevisiae,
and P. jirovecii, the FAS genes are part of a single open read-
ing frame that encodes a trifunctional, multidomain enzyme
that includes dihydroneopterin aldolase, hydroxymethyldi-
hydropterin pyrophosphokinase, and dihydropteroate syn-
thase (DHPS) (15, 34). The FAS genes, including dihydro-
folate synthase, are essential to prokaryotes and lower
eukaryotes since they are dependent on de novo folate biosyn-
thesis and do not possess the capability to actively sequester
exogenous folate. Sulfa drugs such as SMX are competitive
inhibitors of DHPS and work synergistically with TM, which
inhibits microbial dihydrofolate reductase. In P. jirovecii, how-
ever, there is some evidence to suggest that TM is ineffective
and that such treatment is actually sulfamethoxazole mono-
therapy (26, 35). Drug treatment failure of SMX-TM has been
associated with point mutations in the P. jirovecii DHPS gene
in a large number of epidemiological studies (3, 8, 11, 17–23,
27–29, 31–33, 36).
In the absence of a functional P. jirovecii trifunctional FAS
(PjFAS) gene, previous studies of P. jirovecii sulfa drug resis-
tance relied on model systems to determine whether DHPS
mutations conferred SMX resistance (13, 14, 24, 25). These
studies employed the S. cerevisiae FAS (ScFAS) gene as a
surrogate for PjFAS due to their high degree of similarity.
Resistance was analyzed by using homologous complementa-
tion in a DHPS-deleted S. cerevisiae host strain (14). Mutations
were engineered at the analogous ScFAS residues (T597A and
P599S). This model indicated that mutants having two amino
acid substitutions were initially compromised for growth due to
an increased requirement for p-aminobenzoic acid (pABA).
Prototrophs that could grow in the absence of pABA were
isolated. Following adaptation (via continual passage on low-
pABA medium), these double mutants were found to be ca-
pable of improved growth vigor and consequently increased
sulfa drugs resistance. This implicated pABA up-regulation
with sulfamethoxazole resistance. Increased pABA synthesis
probably reflects an adaptive response that compensates for
the reduced pABA binding affinity by the double amino acid
substitutions at the catalytic site of DHPS.
The second study employed heterologous complementation
using the same mutant constructs in a DHPS-disrupted E. coli
strain (13). The E. coli model proved to be more robust than
the S. cerevisiae model. The E. coli model did not have the
pABA-dependent phenotype observed in the S. cerevisiae mod-
el. This indicated that endogenous pABA levels were much
higher in E. coli than in S. cerevisiae as would be expected with
a faster-growing strain. The data from these two studies indi-
cated that (i) mutants having two amino acid substitutions,
T597A and P599S, had increased sulfa drug resistance relative to
the wild type (WT), (ii) mutants having the single amino acid
substitution T597A were more sensitive than the WT, and (iii)
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there was cooperativity between individual mutations that led
to the increased sulfa drug resistance of the double mutants.
Recently, cloning of the trifunctional PjFAS genes and their
heterologous complementation in a DHPS-disrupted E. coli
host strain was achieved (15). This provided an assay method
that permitted a direct assessment of sulfa drug resistance
conferred by mutations observed clinically (T517A and P519S)
in the PjFAS genes. This work endorsed the prediction that the
double mutant (T517A and P519S) had increased sulfamethox-
azole resistance (threefold) relative to the WT clone. These
data provided some explanation for the epidemiological evi-
dence that identified the predominance of the double mutants
clinically (18).
While S. cerevisiae is taxonomically more closely related to
P. jirovecii than E. coli, the E. coli model system proved to be
more robust in evaluating sulfa drug resistance because it
avoided the above-mentioned complicating parameters of the
S. cerevisiae model system. In this study, we utilized heterolo-
gous complementation of PjFAS in the DHPS-disrupted E. coli
host strain to evaluate sulfa drug cross-resistance of PjFAS
mutants (T517A and P519S) against 15 sulfa drugs. We report
the sulfa drugs that were more effective than SMX and dapsone
(DAP), which are currently the drugs of choice to treat PCP.
MATERIALS AND METHODS
Cells, growth media, and transformation. The bacterial strain employed for
molecular cloning and plasmid amplification was Escherichia coli strain MC1061
[araD139 (araABC-leu)7679 galU galK lacX74 rpsL hsdR (rK mK) mcrB].
The growth medium utilized was 1 YT medium (0.5% [wt/vol] yeast extract,
0.8% [wt/vol] tryptone, 0.5% [wt/vol] NaCl).
The DHPS-disrupted E. coli strain was C600 [folP::Kmr F e14 (McrA)
thr-1 leuB6 thi-1 lacY1 glnV44 rfbD1 fhuA21] (9). This strain required 1 YT
medium supplemented with thymidine or genetic complementation with a func-
tional DHPS gene for growth. Cells were made competent by calcium chloride
treatment (7), and transformants were selected by using 1 YT medium sup-
plemented with 50 g of ampicillin/ml and 30 g of kanamycin/ml.
Sulfa drugs. Sulfa drugs used in this study were as follows. DAP, sulfacetamide
(SAM), sulfadimethoxine (SDM), sulfamethoxypyridazine (SMP), sulfamoxole
(SMO), sulfanilamide (SIA), and sulfapyridine (SPD) were purchased from
Sigma Chemical Company. Sulfachloropyridazine (SCP), sulfadiazine (SDZ),
sulfamerazine (SMR), SMX, sulfaquinoxaline (SQX), sulfathiazole (STZ), and
sulfisoxazole (SSA) were purchased from ICN Biomedicals. Dapsone (diamin-
odiphenylsulfone) was purchased from Aldrich Chemical Company. Sulfadoxine
(SDX) was a gift from Roche.
Construction of vectors. (i) pGEX.PjFAS and pET28a.PjFAS. PjFAS expres-
sion constructs in pGEX 4T-2 (glutathione S-transferase tagged) or in pET28a
(six-His tagged) have been described previously (15). In this study, we employed
a pET28a.PjFAS mutant construct (M596T) that permitted heterologous comple-
mentation in E. coli C600folP::Kmr and was identified following random chem-
ical mutagenesis with ethane methyl sulfonate. It is believed to confer increased
DHPS activity, although the precise mechanism has not been dissected. We refer
to this clone as PjFAS M596T.
(ii) pET28a.EcDHPS. E. coli DHPS (EcDHPS) was amplified from E. coli
genomic DNA by using PCR primers 224155 (5-ggtcgcggatccATGAAACTCT
TTGCCCAGGGTACTTCACTGGACCTTAGCC) and 224156 (5-aagcttgtcgac
TTACTCATAGCGTTTGTTTTCCTTTGCAGACAGAGTGGC) having
BamHI sites upstream and SalI sites downstream (lowercase letters signify re-
striction sites). E. coli C600 cells (the parental line of C600folP::Kmr) were
picked from a 1 YT plate, resuspended in 20 l of water, and boiled for 12 min
at 99°C. The cellular debris was then pelleted by centrifugation for 10 min at
20,000  g, and 1 l of the supernatant containing DNA was used in a 100-l
PCR with Vent polymerase (NEB) to yield a PCR fragment of 872 bp. The PCR
fragment was partially digested with BamHI and SalI and cloned into a similarly
digested pET28a vector. This clone was confirmed by diagnostic restriction
digests and by DNA sequencing. The pET28a constructs were used to compare
intrinsic sulfa drug resistance between PjFAS, ScFAS, and EcDHPS.
Synthesis of mutant alleles implicated with sulfa drug resistance in pGEX.
PjFAS. Three alleles having mutations at T517A and P519S (designated ARS,
TRS, and ARP) are found in PCP patients who have been treated with sulfa
drugs (3, 17, 18). Their synthesis was achieved by using a Quikchange XL
sited-directed mutagenesis kit (15) and has been described previously. The oli-
gonucleotides used and alleles generated are summarized in Table 1. A fourth
allele, which has not been reported clinically, was synthesized by using oligonu-
cleotides 259705 and 259706 (Table 1). This synthesis yielded T517V and P519S
for PjFAS and is designated VRS herein. The DNA sequence of mutants was
confirmed by DNA sequencing analysis using a Big Dye Terminator Cycle Se-
quencing Ready Reaction kit (Perkin-Elmer). Functional complementation was
confirmed by transforming the clones into the E. coli C600folP::Kmr strain and
plated onto 1 YT medium minus thymidine.
Analysis of sulfa drug resistance by agar drug diffusion assays. In order to
evaluate the sensitivity or resistance of each DHPS allele to sulfa drugs, drug
diffusion assays were performed as described previously (13). These assays were
performed in 86-mm-diameter petri dishes containing 22.1-ml (0.1-ml) aliquots
of 1 YT medium solidified with 1.5% (wt/vol) agar and supplemented with the
appropriate selective antibiotic. A 6.5-mm hole was made in the center of each
agar plate. Sulfa drugs were prepared immediately before use and dissolved in
dimethyl sulfoxide to 100 mg/ml, and 30 l was loaded onto the center of each
plate and allowed to diffuse through the agar for at least 5 h. In control plates,
30 l of dimethyl sulfoxide was also loaded onto the center of each plate and
allowed to diffuse through the agar. Each experiment was done in quadruplicate.
Clones were precultured in 2 YT broth at 37°C. The E. coli cultures were
harvested while in log-phase growth, washed with 1 phosphate-buffered saline
(0.8% [wt/vol] NaCl, 0.2% [wt/vol] KCl, 1.44% [wt/vol] Na2HPO4, 0.24% [wt/vol]
KH2PO4 [pH 7.4]) and normalized to an A595 of 0.100. Clones were then diluted
500-fold in 1 phosphate-buffered saline prior to inoculation. A six-spoke inoc-
ulation tool (13) was used to inoculate six individual clones radially from the
center of the agar plate. Plates were then incubated at 37°C for 24 h and then
cooled to 4°C until the zones of inhibition were measured. Zones of inhibition
were measured to the nearest half-millimeter and then analyzed by using PRISM
version 4.00 statistical analysis software (for Windows; GraphPad Software, San
Diego, Calif. [http://www.graphpad.com]). Analyses performed were the deter-
minations of means and standard deviations for all data sets. Each data set was
normalized to determine resistance or sensitivity relative to the wild-type allele
(TRP) according to the following equation: [mean radius (mutant)  mean
radius (WT)]/[mean radius (maximum)  mean radius (WT)]  100. The mean
radius (maximum) was the highest measured radius of inhibition (for the mutant
VRS) which was arbitrarily defined as 100% inhibition. The wild-type inhibition
was defined as the baseline or 0% inhibition.
Analysis of the IC50 in broth cultures. Transformants of pGEX 4T-2.PjFAS
were precultured in 1 YT medium containing ampicillin (100 g/ml) and
kanamycin (30 g/ml). Cells were harvested during mid-log-phase growth and
normalized to an A595 of 0.1. Cells were then diluted 200-fold, and 5 l was used
to seed 145 l of 1 YT medium containing 100 g of ampicillin/ml, 30 g of
kanamycin/ml, and sulfa drugs in a 96-well plate (catalog number 167008; Nunc).
SCP was evaluated at 0 to 250 g/ml in 5-g/ml increments. SMP was evaluated
at 0 to 250 g/ml in 5- to 200-g/ml increments. SMX and SDZ were evaluated
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FIG. 1. Inhibition of PjFAS mutants expressed from pGEX 4T-2 determined by using the agar drug diffusion assay. (a) Means and standard
deviations of the zone of inhibition. (b) The mean and standard deviation was calculated for each data set which was then normalized against the
wild-type allele (TRP) and expressed as percent sensitivity or percent resistance relative to the wild type. Analysis was performed by using
GraphPad Prism software, version 4.00.
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at 0 to 1,200 g/ml in 50- to 100-g/ml increments. Cultures were grown at 37°C
for 24 h, the turbidity (A600) was measured by using a Multiskan Ascent micro-
plate reader (Thermo Labsystems), and the data were plotted with Graphpad
PRISM software (version 4.00). Each experiment was performed in quadrupli-
cate and set up by using a Rapidplate liquid-handling robot (QIAGEN). The
50% inhibitory concentration (IC50) was determined to be the drug concentra-
tion required to reduce the turbidity relative to the “no-drug control” by 50%.
RESULTS
Sulfonamide cross-resistance of mutant PjFAS alleles. In
order to assess whether the mutations that conferred SMX
resistance (as previously demonstrated [15]) also conferred
cross-resistance to other sulfa drugs, the growth inhibition of
four mutant clones (VRS, ARS, TRS, and ARP) by 15 sulfa
drugs was evaluated by using an optimized agar drug diffusion
assay described previously (13). The growth inhibition was
analyzed as described in Materials and Methods. The absolute
inhibition of each allele to each sulfa drug is presented in
Fig. 1a. The WT (normalized to 0% inhibition) was compared
against each mutant allele (with the maximum inhibition [for
VRS] normalized to 100%) (Fig. 1b). Each sulfa drug evalu-
ated in this study inhibited the mutants by various degrees. No
consistent resistance profile was observed between the mutants
across the range of sulfa drugs. The magnitude of resistance of
each allele varied depending on the identity of the sulfa drug.
These data were indicative of cross-resistance and suggested
that the resistance conferred by an amino acid substitution (in
the catalytic site of DHPS) does not establish unequivocal or
comparable resistance to all sulfonamides.
While it was observed that the mutant alleles were more
resistant than the WT, there were a number of exceptions
where the mutant alleles were more sensitive than the WT.
Specifically, these exceptions were noted: (i) VRS was more
sensitive than the WT to the sulfa drugs SCP, SMP, and SDZ;
(ii) TRS was more sensitive than the WT to the sulfa drugs
SCP, SMP, SDZ, and SDM; and (iii) ARP was more sensitive
than the WT to SCP. This was also the case in medium that was
prepared by using tryptone which was free of sulfonamide
antagonists (catalog number 1.02239; Merck). Evidently, the
two sulfa drugs (SCP and SMP) had the highest inhibitory
activity overall and appeared to be more effective against the
mutant alleles relative to the WT. SDZ also showed greater
inhibitory potential against the mutants VRS, ARS, and TRS
than the WT, but ARP was more resistant.
The 15 sulfa drugs evaluated against PjFAS were ranked
from highest to lowest inhibitory potential as follows: SCP 
SMP  SMX  STZ  SAM  SDZ  SDM  SMO  SMR
 SIA  SSA  DAP  SQX  SPD  SDX. The drugs SMO
to SDX, which had the lowest inhibitory potential, were also
the least effective against the mutant alleles. The sulfa drugs
SCP to SDM (with the exception of SMX and STZ) showed
some capacity to inhibit the mutant alleles relative to the in-
hibition of the WT. Comparison of the R groups of the “top-
10-ranked” sulfa drugs revealed some common elements (Fig.
2). With the exception of SAM and SSA, the sulfa drugs that
had the highest inhibitory potential have an R group that
consists of an aromatic ring with an N substitution at the ortho
FIG. 2. (a) Structure of pABA and sulfonamides. (b) Three-dimen-
sional structural alignment of SCP and SMP.
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position or adjacent to the amide group. SAM and SSA have
an O substitution at the ortho position. Using this model, it was
evident that DAP, which has been utilized for the treatment of
PCP, had a significantly lower inhibitory potential than SMX.
In fact, DAP was among the least effective inhibitors in this
assay system.
The three-dimensional alignment of SCP and SMP (Fig. 2b)
done by ChemSketch/3D Viewer (version 5.07; ACDlabs soft-
ware, Advanced Chemistry Development Inc., Toronto, On-
tario, Canada) revealed that they maintain an identical three-
dimensional spatial orientation that is unique among the sulfa
drugs evaluated in this study. This result may be an indicator of
a more specific fit of these two drugs into the pABA binding
site of DHPS of PjFAS. Alternatively, these drugs may achieve
higher intracellular concentrations either through a higher dif-
fusion rate constant into E. coli or, conversely, a lower efflux
rate.
Sulfa drug inhibition of DHPS from various species. We
sought to investigate whether (i) the sulfa drug resistance pat-
tern observed using this assay system was a function of the
permeability of specific sulfa drugs through the membrane of
the folP host strain, (ii) the antifolate activity of the 15 sulfa
drugs was comparable between different species of FAS and
DHPS, and (iii) the DHPS mutations were significant variables
in sulfa drug resistance profiles. We therefore compared the
resistance profile of the WT and mutant alleles expressed from
pET28a of PjFAS M596T with those from previous comparable
studies performed with ScFAS (13), Pf-PPPK.DHPS (PfFAS)
(6), and EcDHPS (this study).
Comparison of the ratio of inhibition between the six-His
tagged constructs of EcDHPS, ScFAS, PfFAS, and PjFAS
(M596T, which enabled complementation) revealed no consis-
tent trend between individual drugs across DHPS species (Fig.
3). We therefore ruled out permeability as a significant factor
in the resistance profile of the FAS/DHPS constructs. This did
not, however, discount permeability as a factor in the overall
ranking of inhibitory activity of the sulfa drugs. It is quite
possible that some sulfa drugs may have improved permeability
through the membrane of E. coli compared to those of others.
Each sulfa drug inhibited the DHPS from different species with
various degrees. The inhibition of EcDHPS was consistently
the lowest, and the inhibition of PjFAS M596T was consistently
the highest. ScFAS and PfFAS showed an intermediate level
of resistance relative to EcDHPS and PjFAS M596T. Clearly,
EcDHPS had a significantly higher intrinsic sulfa drug resis-
tance relative to ScFAS and PjFAS M596T. This finding indi-
cated that the DHPS sequence, and therefore structure, from
different species had a significant impact on sulfa drug resis-
tance. This was also evident by the observation that the ranking
of inhibitory potential of sulfa drugs was different for each
DHPS sequence (DHPS from four different species). (Table
2). These data indicated that SCP was consistently the most
FIG. 3. Inhibition of EcDHPS, PfFAS, ScFAS, and PjFAS M596T constructs (means and standard deviations) expressed from pET28a
determined by using the agar drug diffusion assay.
TABLE 2. Ranking of inhibitory potential of sulfa drugs for DHPS
from various species in the E. coli C600FolP strain
DHPS
species
Sulfa drug by rank
1 2 3 4 5 6
S. cerevisiae SCP STZ SMX SAM SSA SMP
P. jirovecii SCP SMP SMX STZ SAM SDZ
P. falciparum SCP SAM SMO STZ SIA SMX
E. colia SCP SMX SSA SMP STZ SAM
a WT only.
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inhibitory sulfa drug. However, the ranking of the remaining
14 sulfa drugs differed from species to species. Furthermore,
a different pattern of resistance was noted between PjFAS
(T517A and P519S) and ScFAS (T597A and P599S) mutants (10).
This result indicated that identical amino acid substitutions at
comparable sites can have significantly different resistance out-
comes, implicating subtle structural differences between the
individual DHPS superstructures.
Determination of IC50s of PjFAS alleles to SCP, SMP, SMX,
and SDZ. In order to quantitatively determine the resistance of
the four drugs found to be most inhibitory to the drug-resistant
alleles, liquid growth inhibition assays were performed with
96-well microtiter plates. In agreement with the drug diffusion
assays, these data indicated that SCP and SMP had signifi-
cantly higher inhibitory potential than SMX (Fig. 4). The MIC
(the concentration required to inhibit 100% of growth) of SCP
was in the order of 60 g/ml (0.2 mM), and the MIC of SMP
was in the order of 150 g/ml (0.5 mM), while the MIC of
SMX and SDZ was closer to 700 g/ml (2.8 mM).
A finer discrimination of resistance between each allele
could be discerned by determining the IC50 (Fig. 4 and Table
3). It was determined that the resistance pattern of each allele
relative to the WT was consistent with the results of the agar
drug diffusion assay (with one exception). In agreement with
the SDZ drug diffusion assays, the mutants TRS, VRS, and
ARS were more sensitive than the WT, while ARP was more
resistant than the WT in the liquid growth inhibition experi-
ment. Also in agreement with the SMX drug diffusion assays,
it was found that all mutant alleles were more resistant than
the WT in the liquid growth inhibition experiment. Further-
more, as predicted by the SMP drug diffusion assay, VRS and
TRS were more sensitive than the WT in the liquid growth
inhibition experiment. ARS was slightly more resistant than
the WT (but was within experimental error), and ARP was
found to be more resistant than the WT. Finally, as predicted
by the SCP drug diffusion assay, TRS and VRS were more
sensitive than the WT, while ARS was more resistant. ARP
was found to be more resistant than the WT in the liquid
growth inhibition assay, which was contrary to the agar drug
diffusion data. Despite this latter incongruous result, it was ev-
ident that like SDZ, SMP was capable of inhibiting the natu-
rally occurring double mutant ARS and single mutant TRS to
a greater degree than the WT.
The discordant data between the agar drug diffusion assay
and the liquid growth inhibition assay for SCP remains unre-
solved. However, it was not surprising that sulfa drug resis-
tance results do not always translate from agar to liquid media.
A case in point is the sulfamethoxazole resistance of the PjFAS
mutants determined previously (15) by using the validated
Etest methodology. The MIC of 1 to 3 g/ml determined in
that study does not correlate to the MIC determined with
liquid medium, which was in the order of 600 g/ml. Clearly,
the dynamics of nutrient, sulfa drug, and sulfa adduct diffusion
(30) in and out of the cell are significantly different between
agar and liquid.
DISCUSSION
A large amount of epidemiological data has linked the emer-
gence of mutations in PjFAS to the exposure to sulfa drugs, but
direct evidence demonstrating that such mutations confer re-
sistance in P. jirovecii has only recently emerged (15). That
previous work demonstrated that amino acid substitutions in
PjFAS T517A and P519S (ARS) conferred a threefold-increased
level of SMX resistance relative to the WT and that the indi-
TABLE 3. IC50 of E. coli C600folP::Km
r transformed
with mutant or WT PjFAS
Drug
IC50 (g/ml)
TRP ARP TRS ARS VRS
SCP 11.7 15.1 6.4 16.3 11.4
SMP 28 37 15 27 18
SMX 38 58 53 121 74
SDZ 171 275 48 98 60
FIG. 4. Liquid growth inhibition assays of each PjFAS mutant against four sulfonamide drugs (SCP, SMP, SMX, and SDZ) performed in
96-well microtiter plates; the percent inhibition relative to the no-drug control is shown. Each point represents the mean of quadruplicate
experiments, and the standard errors are shown by the error bars.
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vidual amino acid substitutions functioned cooperatively, re-
sulting in the elevated resistance of double mutant ARS.
The cross-resistance data presented herein provide a similar
overall resistance profile and support the previous findings of
cooperativity between individual mutations that resulted in
increased resistance of the double mutant ARS. This point was
not absolutely true nor was it without exception in this cross-
resistance study. The single mutant ARP was more resistant
than the double mutant ARS for five drugs (SCP, SMP, SAM,
SDZ, and SMR). Clearly, cooperativity between individual
amino acid substitutions that lead to higher resistance is de-
pendent on the drug and its fit into the pABA binding site of
DHPS.
Of particular interest was the finding that the mutant ARS,
which is the clinical isolate observed most frequently, was con-
siderably more resistant than the synthetic double mutant VRS
and the single mutants ARP and TRS. Liquid growth inhibi-
tion studies confirmed previous findings (15) which showed a
threefold-increased level of SMX resistance (IC50) of ARS
compared to that of the WT. However, the absolute drug con-
centration required was significantly higher in liquid growth
inhibition assays than in agar drug diffusion assays. This may be
explained by the significant differences in drug and nutrient
diffusion in the two medium types.
This finding is in contrast with previous findings with S. cer-
evisiae model systems (13, 14) that showed VRS to be more
resistant than ARS. This finding highlights that the role of res-
idues T517 and P519 of PjFAS (or T597A and P599S of ScFAS)
is highly conserved in terms of conferring sensitivity or resis-
tance to sulfa drugs between homologs of FAS, the tertiary
context of these residues in the overall DHPS sequence and
structure is critically important. That is, subtle differences in
the catalytic site can have profound effects on drug resistance.
Clearly, VRS is significantly more resistant than ARS in the S.
cerevisiae FAS structure, but ARS is significantly more resis-
tant than VRS in the P. jirovecii FAS structure.
The data presented in this study demonstrated that the mu-
tations T517A and P519S in PjFAS led to cross-resistance for
most sulfa drugs evaluated. Clearly, mutations that lead to re-
sistance against one drug can have broad implications for re-
sistance against an entire class of drug. This finding would be
consistent with a highly conserved drug binding site and is
supported by the consistent resistance trend observed from
previous model studies (13). Clearly, subtle structural differ-
ences in the pABA binding site dictate drug specificity and
resistance for different species as evidenced by the different
intrinsic resistance-susceptibility pattern to sulfa drugs (Table
2). Four DHPS structures have been solved, E. coli (1), Staph-
ylococcus aureus (10), Mycobacterium tuberculosis (4), and S.
cerevisiae (M. C. Lawrence et al., unpublished data). It is evi-
dent that the pterin binding site is exquisitely conserved, while
the pABA binding site shows significant structural variation
(despite sequence conservation) and is reflected by the ob-
served variation in sulfa susceptibility between species. SCP
consistently showed the highest inhibitory potential for all
DHPS enzymes, indicating that some sulfonamides may have
broad-spectrum activity against DHPS from various species
while some sulfonamides can act with greater species specific-
ity. On this last point, there seemed considerable overlap in the
efficacy of the top-6-ranked sulfa drugs across four different
species of DHPS (Table 2). Selective diffusion through the E.
coli membrane may be a significant contributor to the higher
activity of SCP. If so, drug diffusion would be a key criterion to
investigate for the selection of a species-specific inhibitor.
PjFAS M596T was observed to have higher susceptibility to
sulfa drugs than EcDHPS and ScFAS. Based on the ranking of
inhibitory activity for various sulfa drugs, it is possible that PCP
therapy could be more efficacious by the choice of a sulfa drug
(such as SCP or SMP) which had higher activity relative to
SMX. It would seem that these data can be interpreted to
suggest that antifolate compounds (sulfonamides or otherwise)
can be selected through screening to have greater drug speci-
ficity to individual DHPS species. Furthermore, antifolates
such as SCP that had the highest activity against the four
DHPS species (including Pf-PPPK.DHPS, as described by Ber-
glez et al. [6]) indicates that antifolates that have broad-spec-
trum activity can be identified.
Of the 15 drugs evaluated, 2 drugs were noted to be con-
spicuously superior to SMX in their inhibitory potential: SCP
and SMP, which were ranked first and second. SMX, which has
been the sulfa drug of choice to treat or prevent PCP infec-
tions, was ranked third. More importantly, it was observed that
SDZ (ranked sixth), was superior to all other drugs due to its
ability to effectively inhibit the mutant alleles (ARS, VRS, and
TRS) to a greater degree than the WT. SDZ was the only drug
capable of inhibiting ARS. These features make these three
sulfa drugs worthy candidates for further evaluation against
PCP. These data support previous findings which demon-
strated that SMP was effective against a mouse model of PCP
(5, 12).
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